SCHEMBL668240

SCHEMBL668240

NOC(=O)C1CCCC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL668534 0.97 CES2 (0.50)
SCHEMBL27943933 0.97 CES2 (0.50)
SCHEMBL27383124 0.97 CES2 (0.50)
Hydrochloric Acid SCHEMBL27128353 0.97 CES2 (0.43)
SCHEMBL27944970 0.95 CES2 (0.48)
Hydrochloric Acid SCHEMBL12099257 0.95 CES2 (0.48)
Hydrochloric Acid SCHEMBL28392169 0.95 CES2 (0.48)
SCHEMBL27925808 0.95 CES2 (0.48)
SCHEMBL668274 0.94
SCHEMBL24684871 0.88 KMT2A (0.36)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105412640-A Medicine composition for treating cervical ectropion and preparing method thereof ZHANG YUN 2016-03-23 CN claimed
CN-105327282-A Medicine composition for treating gynecological uterine cervicitis and preparing method thereof SUN XIULIAN 2016-02-17 CN claimed
US-20250000942-A1 PEPTIDES AND METHODS OF TRANSPLANTATION AND RESTORATIVE ORGAN FUNCTION PRINCE BIOTECH, LLC 2025-01-02 US disclosed
CN-114269367-A Therapeutic peptides 科巴公司 2022-04-01 CN disclosed
CN-113518784-A Therapeutic peptides 科巴公司 2021-10-19 CN disclosed
CN-110352068-A The immunity receptor and its application method of synthesis 南加利福尼亚大学 2019-10-18 CN disclosed
CN-110072883-A The relevant peptide of therapeutic MOTS-C 科巴公司 2019-07-30 CN disclosed
US-10196428-B2 Modification of cupredoxin derived peptides NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2019-02-05 US disclosed
US-10149896-B2 MHC-I restricted epitopes containing non-natural amino acid residues PURDUE PHARMA L.P. (US) 2018-12-11 US disclosed
US-20170319670-A1 MHC-I Restricted Epitopes Containing Non-Natural Amino Acid Residues PURDUE PHARMA L.P. (US) 2017-11-09 US disclosed
US-20170174729-A1 MODIFICATION OF CUPREDOXIN DERIVED PEPTIDES AND METHODS OF USE THEREOF NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2017-06-22 US disclosed
WO-2005098435-A2 PEPTIDES AND PEPTIDOMIMETICS BINDING TO CD23 UNIVERSITE BORDEAUX 2 (FR) 2005-10-20 WO disclosed
EP-1250340-B1 METHODS AND COMPOUNDS FOR INHIBITING MRP1 LILLY CO ELI (US) 2004-11-17 EP disclosed
US-20040176405-A1 Methods and compounds for inhibitting MRP1 KROIN JULIAN (US) 2004-09-09 US disclosed
US-6743794-B2 MULTIDRUG RESISTANCE PROTEIN; CANCER; 3-(9-CHLORO-3-METHYL-4-OXO-5H-ISOXAZOLO(4,3-C)QUINOLIN-5-YL)) CYCLOHEXYL)-2-PIPERIDYLACETAMIDE ELI LILLY AND COMPANY 2004-06-01 US disclosed
US-20030100576-A1 Methods and compounds for inhibiting mrp1 ELI LILLY AND COMPANY 2003-05-29 US disclosed
EP-1250340-A1 METHODS AND COMPOUNDS FOR INHIBITING MRP1 ELI LILLY AND COMPANY (US) 2002-10-23 EP disclosed
EP-1147078-A1 ACETYLENIC (BETA)-SULFONAMIDO AND PHOSPHINIC ACID AMIDE HYDROXAMIC ACID TACE INHIBITORS American Cyanamid Company (US) 2001-10-24 EP disclosed
WO-2001046199-A1 METHODS AND COMPOUNDS FOR INHIBITING MRP1 ELI LILLY AND COMPANY (US) 2001-06-28 WO disclosed
WO-2000044711-A1 ACETYLENIC $G(b)-SULFONAMIDO AND PHOSPHINIC ACID AMIDE HYDROXAMIC ACID TACE INHIBITORS AMERICAN CYANAMID COMPANY (US) 2000-08-03 WO disclosed